I am a
Home I AM A Search Login

Papers of the Week

2021 Dec 23

J Allergy Clin Immunol

An Open-Label, Proof-of-Concept Study of Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria.


Altrichter S, Staubach P, Pasha M, Singh B, Chang AT, Bernstein JA, Rasmussen HS, Siebenhaar F, Maurer M
J Allergy Clin Immunol. 2021 Dec 23.
PMID: 34954198.


Chronic urticaria (CU) is a debilitating mast cell-driven disease, often refractory to standard therapy (i.e., antihistamines). Lirentelimab, an anti-Siglec-8 monoclonal antibody, selectively inhibits mast cells and depletes eosinophils.